![](https://scdn.x-mol.com/css/images/icon-new-link.png)
样式: 排序: IF: - GO 导出 标记为已读
-
A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-18 David J. Young
In this issue, the COMMODORE 11 and COMMODORE 22 trials of crovalimab for previously treated and treatment-naïve paroxysmal nocturnal hemoglobinuria, respectively, are presented, demonstrating efficacy and safety for both patient populations in comparison with the benchmark, eculizumab. Paroxysmal nocturnal hemoglobinuria (PNH) is a hemolytic anemia characterized by sometimes painful intravascular
-
Risk of myeloproliferative neoplasms among U.S. Veterans from Korean, Vietnam, and Persian Gulf War eras Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-18 Andrew Tiu, Zoe McKinnell, Shanshan Liu, Puneet Gill, Martha Antonio, Zoe Shancer, Nandan Srinivasa, Guoqing Diao, Ramesh Subrahmanyam, Craig M. Kessler, Maneesh Jain
The Promise to Address Comprehensive Toxics (PACT) Act expanded U.S. Veterans' health care and benefits for conditions linked to service‐connected exposures (e.g., Burn Pits, Agent Orange). However, myeloproliferative neoplasms (MPN) are not recognized as presumptive conditions for Veterans exposed to these toxic substances. This study evaluated the development of MPN among U.S. Veterans from the Korean
-
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-17 Sanam Loghavi, Qing Wei, Farhad Ravandi, Andres E. Quesada, Mark J. Routbort, Shimin Hu, Gokce A. Toruner, Sa A. Wang, Wei Wang, Roberto N. Miranda, Shaoying Li, Jie Xu, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Ghayas C. Issa, Hagop M. Kantarjian, L. Jeffrey Medeiros, Guilin Tang
Cytogenomic characterization is crucial for the classification and risk stratification of acute myeloid leukemia (AML), thereby facilitating therapeutic decision‐making. We examined the clinical utility of optical genome mapping (OGM) in 159 AML patients (103 newly diagnosed and 56 refractory/relapsed), all of whom also underwent chromosomal banding analysis (CBA), fluorescence in situ hybridization
-
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go? Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-17 Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, Courtney D. DiNardo
-
Correction to “Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma” Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-12
Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Am J Hematol. 2023 Oct;98(10):1540–1549. doi: 10.1002/ajh.27023. Epub 2023 Jul 8. PMID: 37421603. In this article, we forgot to acknowledge that the work was supported
-
Correction to “Risk factors for severe infection and mortality in patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis” Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-12
Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Am J Hematol. 2023 Jan;98(1):49–55. doi: 10.1002/ajh.26762. Epub 2022 Oct 24. PMID: 36226510. In
-
-
Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-09 Peng Zhao, Zhuo‐Yu An, Hai‐Xia Fu, Hui‐Xin Liu, Cheng‐Jie Feng, Qiu‐Sha Huang, Jin Wu, Ye‐Jun Wu, Li‐Ping Yang, Qing‐Yuan Qu, Yu‐Xiu Chen, Meng‐Lin Li, Chen‐Cong Wang, Qi Chen, Xiao‐Lu Zhu, Yun He, Yuan‐Yuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, Ying‐Jun Chang, Xiao‐Su Zhao, Xiang‐Yu Zhao, Xiao‐Jun Huang, Xiao‐Hui Zhang
Patients with steroid‐resistant or relapsed immune thrombocytopenia (ITP) suffer increased bleeding risk and impaired quality of life. Baricitinib, an oral Janus‐associated kinases (JAK) inhibitor, could alleviate both innate and adaptive immune disorders without inducing thrombocytopenia in several autoimmune diseases. Accordingly, an open‐label, single‐arm, phase 2 trial (NCT05446831) was initiated
-
Immune thrombocytopenia newly diagnosed during pregnancy: Outcome for mothers and neonates and comparison with chronic immune thrombocytopenia during pregnancy Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-09 Stéphanie Guillet, Valentine Loustau, Emmanuelle Boutin, Odile Souchaud‐Debouverie, Nathalie Costedoat Chalumeau, Laurent Pascal, Laurent Gilardin, Louis Terriou, Julie Graveleau, Thibault Comont, Helene Henique, Quitterie Reynaud, Matthieu Mahévas, Marc Michel, Florence Canoui‐Poitrine, Bertrand Godeau
The incidence of many autoimmune diseases is increased in women of childbearing age. Recent studies gave reassuring data for women with preexisting immune thrombocytopenia (ITP) who want to become pregnant.1, 2 In particular, we recently confirmed that pregnancy does not increase the risk of severe bleeding.2 Little is known about the outcome of ITP diagnosed during pregnancy, and conflicting results
-
Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-06 Metodi Balev, Victor Zibara, Grace Van Hyfte, Jonathan Feld, Marina Kremyanskaya, Michelle Becker, Alla Keyzner, Alan H. Shih, Bridget Marcellino, Hannah Levavi, Lewis Silverman, John Mascarenhas, Douglas Tremblay
-
At what COST?: A prospective longitudinal cohort assessment of financial toxicity, quality of life, and associated risk factors in patients with plasma cell disorders Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-05 Rahma M. Warsame, Walker M. Schmidt, Angela Dispenzieri, Amylou C. Dueck
-
Anxiety and depression are associated with heightened risk of incident deep vein thrombosis: Mediation through stress‐related neural mechanisms Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-05 Rachel P. Rosovsky, Kenechukwu Mezue, Charbel Gharios, Giovanni Civieri, Alexander Cardeiro, Hadil Zureigat, Hui Chong Lau, Roger K. Pitman, Lisa Shin, Shady Abohashem, Michael T. Osborne, Farouc A. Jaffer, Ahmed Tawakol
-
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-03 Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
Disease overviewEpstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an aggressive B‐cell lymphoma associated with EBV infection included in the WHO classification of lymphoid neoplasms since 2016. Although historically associated to poor prognosis, outcomes seem to have improved in the era of chemoimmunotherapy.DiagnosisThe diagnosis is established
-
Targeting exhausted cytotoxic T cells through CTLA-4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-02 Lara Tavernari, Sebastiano Rontauroli, Ruggiero Norfo, Margherita Mirabile, Monica Maccaferri, Barbara Mora, Elena Genovese, Sandra Parenti, Chiara Carretta, Elisa Bianchi, Matteo Bertesi, Francesca Pedrazzi, Elena Tenedini, Silvia Martinelli, Maria Teresa Bochicchio, Paola Guglielmelli, Leonardo Potenza, Alessandro Lucchesi, Francesco Passamonti, Enrico Tagliafico, Mario Luppi, Alessandro Maria Vannucchi
-
Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)—A randomized, placebo‐controlled phase II feasibility/pilot study Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-02 James F. Casella, Dana K. Furstenau, Robert J. Adams, Donald J. Brambilla, Jeffrey D. Lebensburger, James J. Fehr, Lori C. Jordan, Allison A. King, Rebecca N. Ichord, Robert C. McKinstry, Michael A. Kraut, Dennis W. Shaw, Desiree A. White, Donna A. Whyte‐Stewart, Radhika Avadhani, Emily A. Barron‐Casella, Alicia D. Cannon, Cyd K. Eaton, Kristin A. Riekert, Joanne E. Shay, Cynthia A. Smith‐Seidel, Diane
Central nervous system (CNS) injury is common in sickle cell disease (SCD) and occurs early in life. Hydroxyurea is safe and efficacious for treatment of SCD, but high‐quality evidence from randomized trials to estimate its neuroprotective effect is scant. HU Prevent was a randomized (1:1), double‐blind, phase II feasibility/pilot trial of dose‐escalated hydroxyurea vs. placebo for the primary prevention
-
Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-02 Eirini Katodritou, Dimitra Dalampira, Sosana Delimpasi, Ioannis Ntanasis‐Stathopoulos, Fryni Karaolidou, Annita‐Ioanna Gkioka, Vasiliki Labropoulou, Emmanouil Spanoudakis, Theodora Triantafyllou, Maria Kotsopoulou, Eyrydiki Michalis, Chrysanthi Vadikolia, Theodosia Papadopoulou, Aggeliki Sevastoudi, Michael Michael, Aikaterini Daiou, Aikaterini Pentidou, Ioannis Kostopoulos, Vasiliki Palaska, Maria
Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS‐MM between 2000 and 2022. A matched‐control group of MM patients without CNS‐MM was used for comparisons. Median age was 63 years. Median time to CNS‐MM was 28 months; 6/54 experienced CNS‐MM at MM diagnosis. Abnormal lactate dehydrogenase
-
Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis Am. J. Hematol. (IF 10.1) Pub Date : 2024-07-01 Claudia Pérez Carretero, Teresa González, Miguel Quijada Álamo, Gian Matteo Rigolin, Adrian Dubuc, Ángela Villaverde Ramiro, Alberto Rodríguez‐Sánchez, Araceli Rubio, Julio Dávila, Mª. Jesús Vidal, Isabel González Gascón y Marín, José‐Ángel Hernández‐Rivas, Rocío Benito, Virginia Volpe, Matthew S. Davids, Jeremy S. Abramson, Antonio Cuneo, Paola Dal Cin, Ana‐Eugenia Rodríguez‐Vicente, Jesús‐María Hernández‐Rivas
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, with survival times ranging from months to decades, reflecting a great biological diversity. Classical cytogenetical models allow to classify patients in different risk subgroups according to the presence of certain chromosomal aberrations, being the most common the 13q deletion (del(13q)), 17p deletion (del(17p)), 11q deletion
-
Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-29 S. Vincent Rajkumar
Disease overviewMultiple myeloma accounts for approximately 10% of hematologic malignancies.DiagnosisThe diagnosis requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) attributable to the plasma cell disorder, bone marrow clonal plasmacytosis
-
An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-27 Yoshihiro Inamoto, Koji Kato, Toshiro Kawakita, Yasushi Onishi, Ken‐ichi Matsuoka, Soichi Shiratori, Kazuhiro Ikegame, Nobuhiro Hiramoto, Masako Toyosaki, Yuta Katayama, Shun Murayama, Yuji Sasagawa, Yoshinobu Maeda, Kiyohiko Hatake, Takanori Teshima
Belumosudil mesylate is a selective Rho‐associated coiled‐coil kinase 2 inhibitor with immunomodulatory and antifibrosis effects. This multicenter, open‐label, single‐arm study evaluated belumosudil 200 mg once daily as second or subsequent line of therapy (LOT) in 21 Japanese patients ≥12 years of age with steroid‐dependent/steroid‐resistant chronic graft‐versus‐host disease (cGVHD). The primary endpoint
-
Hereditary chronic neutrophilic leukemia in a four‐generation family without transformation to acute leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-27 Amanda Lance, Zane Chiad, Sara L. Seegers, Sarah‐Catherine Paschall, Kendra Drummond, Nury M. Steuerwald, Hsih‐Te Yang, Jenny Chen, Peter M. Voorhees, Belinda R. Avalos, Lawrence J. Druhan
-
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-26 Phillip Scheinberg, Diego Villa Clé, Jin Seok Kim, Erfan Nur, Mustafa N. Yenerel, Wilma Barcellini, Debora Bonito, Valentina Giai, Marek Hus, YooJin Lee, Cristina Barrenetxea Lekue, Jens Panse, Yasutaka Ueda, Simon Buatois, Brittany Gentile, Anna Kiialainen, Himika Patel, Sasha Sreckovic, Marianne Uguen, John Edwards, Zsolt Nagy, Austin G. Kulasekararaj
-
Null‐type SH2B3 mutations are potential drivers in a subset of Ph‐negative myeloproliferative neoplasms Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-25 Xi Zhang, Yi Ding, Peng Li, Kirk Bourgeois, Aruna Rangan, Jennifer L. Herrick, Animesh Pardanani, Dong Chen, David Viswanatha, Rong He, Gang Zheng
Philadelphia-negative myeloproliferative neoplasms (MPNs) are characterized predominantly by mutations in JAK2, CALR, and MPL genes, as well as a small number of other genes in so-called “triple-negative” MPNs. JAK2, CALR, and MPL mutations are mostly mutually exclusive and lead to constitutive JAK–STAT signaling pathway activation. SH2B3 encodes the lymphocyte adaptor (LNK) protein, which is a member
-
Starry sky pattern predicts RAS pathway activation in NPM1‐mutated acute myeloid leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-22 Alessandra Venanzi, Valeria Cardinali, Vincenzo Perriello, Francesco Albano, Gaetano Cimino, Giovanni Martino, Andrea Marra, Paolo Sportoletti, Vibeke Andresen, Bjorn T. Gjertsen, Simona Sica, Patrizia Chiusolo, Maria Paola Martelli, Enrico Tiacci, Brunangelo Falini
CONFLICT OF INTEREST STATEMENT Brunangelo Falini holds a patent on NPM1 mutants (number 102004901256449). Maria Paola Martelli declares honoraria/consultancy at the scientific advisory board for AbbVie, Amgen, BMS, Delbert, Janssen, Novartis, Pfizer, and Jazz Pharmaceuticals. The other authors declare no conflict of interest.
-
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-20 Sylvain Garciaz, Pierre‐Yves Dumas, Sarah Bertoli, David A. Sallman, Justine Decroocq, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Chantal Himberlin, Pierre Peterlin, Sarah Bonnet, Onyee Chan, Jeffrey Lancet, Rami Komrokji, François Vergez, Nicolas Chapuis, Tatiana Raskovalova, Adriana Plesa, Anne‐Catherine Lhoumeau, Ariane
Venetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE‐A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax‐azacitidine due to poor tolerance. Sixty‐two
-
Real-world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-19 Calia Torres, Najibah Galadanci, Jeremy Osborn, Julie Kanter
To the Editor: Sickle cell disease (SCD) is the most common clinically relevant inherited blood disorder resulting in organ dysfunction, acute and chronic pain, and early mortality.1, 2 Acute painful episodes (also known as sickle cell crisis) are common in SCD and chronic pain is reported in over 50% of adults. The majority of the acute care in SCD is caused by acute pain episodes (APE) which often
-
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-17 Alexander Röth, Guangsheng He, Hongyan Tong, Zenghua Lin, Xiaoqin Wang, Chatree Chai-Adisaksopha, Je-Hwan Lee, Andres Brodsky, Chattree Hantaweepant, Teresita E. Dumagay, Roberta Demichelis-Gómez, Ponlapat Rojnuckarin, Jing Sun, Martin Höglund, Jun Ho Jang, Anna Gaya, Fernando Silva, Naoshi Obara, Richard J. Kelly, Leigh Beveridge, Simon Buatois, Sammy Chebon, Brittany Gentile, Pontus Lundberg, Sasha
-
Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-17 Moshe Mittelman, David H. Henry, John A. Glaspy, Anil Tombak, Rosemary Harrup, Inho Kim, Krzysztof Mądry, Barbara Grabowska, Tyson Lee, Katharina Modelska
-
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-15 Bianca Rocca, Alberto Tosetto, Giovanna Petrucci, Elena Rossi, Silvia Betti, Denise Soldati, Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Alfredo Dragani, Mauro Di Ianni, Paola Ranalli, Francesca Palandri, Nicola Vianelli, Eloise Beggiato, Giuseppe Lanzarone, Marco Ruggeri, Giuseppe Carli, Elena Maria Elli, Rossella Renso, Maria Luigia Randi, Irene Bertozzi, Giuseppe Gaetano Loscocco, Alessandra
Patients with essential thrombocythemia (ET) are treated with once-daily low-dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short-term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice-daily aspirin dosing restores persistent platelet thromboxane (TX) inhibition. However, the long-term pharmacodynamic efficacy, safety
-
Still high risk? A review of translocation t(14;16) in multiple myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-14 Hira Mian, Martin Kaiser, Rafael Fonseca
Multiple myeloma (MM) is a heterogeneous and complex disease, both in mutational biology as well as in the clinical presentation of patients. While tailored and biomarker-targeted therapy remains the direct goal for patient-centric management, existing therapies in MM remain largely uniform. Translocation t(14;16) is a rare primary genetic event found in less than 5% of patients with newly diagnosed
-
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-12 Naseema Gangat, Amritpal Singh, Rimal Ilyas, Giuseppe Gaetano Loscocco, Michelle Elliott, Kebede Begna, Animesh Pardanani, Ayalew Tefferi
-
Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-11 Hazim S. Ababneh, Andrea K. Ng, Matthew J. Frigault, Caron A. Jacobson, Chirayu G. Patel
CAR T-cell therapy has significantly improved survival for relapsed/refractory large B cell lymphoma (LBCL), but bridging therapy may be required as patients await CAR T infusion.1 Bridging radiation therapy (RT) can control locally progressive disease, alleviate symptomatic disease, and debulk tumors with high metabolic volume without increasing the toxicities of subsequent CAR T-infusion.1 Our group
-
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-11 Ioannis V. Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, Panagiotis Malandrakis, Chrysanthi Panteli, Evangelos Eleutherakis-Papaiakovou, Nikolaos Angelis, Vasiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Panagiotis Bakouros, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Nikolaos Paschalidis, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios
-
Correction to “Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials” Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-11
Sidiqi MH, Al Saleh AS, Kumar SK, Leung N, Jevremovic D, Muchtar E, Gonsalves WI, Kourelis TV, Warsame R, Buadi FK, Lacy MQ, Kyle RA, Go R, Hobbs M, Dispenzieri A, Dingli D, Hayman SR, Gertz MA, Rajkumar SV, Kapoor P. Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials. Am J Hematol. 2021;96(9):1131–1136. doi: 10.1002/ajh.26269. In this article we forgot to acknowledge
-
Correction to “Prognostic significance of acquired 1q22 gain in multiple myeloma” Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-10
Audil HY, Cook JM, Greipp PT, et al. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol. 2022;97(1):52-59. In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21). We apologize for this error.
-
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-10 Arnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, Myriam Labopin, Igor Wolfgang Blau, Nicolaus Kröger, Tobias Gedde-Dahl, Thomas Schroeder, David Burns, Urpu Salmenniemi, Alessandro Rambaldi, Goda Choi, Régis Peffault de Latour, Jan Vydra, Henrik Sengeloev, Matthias Eder, Stephan Mielke, Edouard Forcade, Alexander Kulagin, Fabio Ciceri, Mohamad Mohty
We compared relapse incidence (RI) post-unrelated transplantation with post-transplant cyclophosphamide (PTCy) versus no PTCy graft-versus-host disease (GVHD) prophylaxis, in 7049 acute myeloid leukemia (AML) patients in remission, 707 with PTCy, and 6342 without (No PTCy). The patients in the PTCy group were younger, 52.7 versus 56.6 years (p < .001). There were more 9/10 donors in the PTCy group
-
Correction to “Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival” Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-10
Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. Am J Hematol. 2023;98(3):413–420. doi: 10.1002/ajh.26806. In this article
-
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-10 Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus G. Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski
Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients increasingly challenging. We report the final analysis of a single-arm, phase 2 study evaluating the oral proteasome inhibitor (PI) ixazomib combined with daratumumab and dexamethasone (IDd; NCT03439293). Sixty-one RRMM patients
-
Correction to “Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients” Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-07
Mellors PW, Kourelis T, Go RS, et al. Characteristics and risk factors for thrombosis in POEMS syndrome: a retrospective evaluation of 230 patients. Am J Hematol. 2022;97(2):209-215. In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21). We apologize for this error.
-
Targeting anemia in myeloid neoplasms Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-05 Naseema Gangat, Ayalew Tefferi
-
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-06 Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Ilaria Colugnat, Raffaela Aquila, Manjola Balliu, Chiara Maccari, Simone Romagnoli, Chiara Paoli, Elena Nacca, Lorenzo Fagiolo, Margherita Maffioli, Tiziano Barbui, Francesco Passamonti, Alessandro M. Vannucchi
The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains debated. We prospectively measured changes in JAK2 and CALR VAF in 77 patients with polycythemia
-
Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)” Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-04
Visram A, Hayman SR, Dispenzieri A, et al. Am J Hematol. 2023;98(8):1277-1285. doi: 10.1002/ajh.26990. In this article, we forgot to acknowledge that the work was supported by the Paul Calabresi K12 Career Development Award (CA90628-21). We apologize for this error.
-
Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-04 Aung M. Tun, Romil D. Patel, Frederique St-Pierre, Evguenia Ouchveridze, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal, Priyanka A. Pophali, Timothy S. Fenske, Reem Karmali, Sairah Ahmed, Patrick B. Johnston
Chimeric antigen receptor T-cell (CAR-T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B-cell lymphoma (LBCL), remains underutilized in older patients due to limited clinical data. We therefore studied the safety and efficacy of CAR-T therapy in older patients with RR LBCL in the real-world setting. Patients aged ≥65 years with RR LBCL, treated with anti-CD19
-
BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-01 Karin Bauer, Alexander Hauswirth, Karoline V. Gleixner, Georg Greiner, Johannes Thaler, Peter Bettelheim, Yüksel Filik, Elisabeth Koller, Gregor Hoermann, Philipp B. Staber, Wolfgang R. Sperr, Felix Keil, Peter Valent
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life‐threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti‐leukemic efficacies of the small‐molecule
-
Plasmablastic lymphoma in the pleural cavity Am. J. Hematol. (IF 10.1) Pub Date : 2024-06-01 Aditi Manjeri, Shir Ying Lee, Siok-Bian Ng, Chun-Tsu Lee
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
The prognostic value of blood cellular indices in pulmonary embolism Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-30 Fakiha Siddiqui, Alfonso Tafur, Mushtaq Hussain, Alberto García-Ortega, Amir Darki, Jawed Fareed, David Jiménez, Behnood Bikdeli, Francisco Galeano-Valle, José Luis Fernández-Reyes, Montserrat Pérez-Pinar, Manuel Monreal
Prognostication in acute pulmonary embolism (PE) requires reliable markers. While cellular indices such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) appear promising, their utility in PE prognostication needs further exploration. We utilized data from the RIETE registry and the Loyola University Medical Center (LUMC) to assess
-
Molecular landscape of mature B‐cell lymphoproliferative disorders with BCL3‐translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-31 Lauren Véronèse, Hedi Bensaber, Louis‐Thomas Dannus, Gaetan Giannone, Christopher Choiset, Corentin Grimpret, Nassera Abermil, Estelle Balducci, Audrey Bidet, Elise Chapiro, Lucile Couronné, Agnès Daudignon, Nathalie Douet‐Gilbert, Virginie Eclache, Baptiste Gaillard, Jean‐Baptiste Gaillard, Faten Hsoumi, Christine Lefebvre, Nathalie Nadal, Marie‐Joelle Mozziconacci, Dominique Penther, Bénédicte Ribourtout
The classical (14;19)(q32;q13)/IGH::BCL3 or variant translocations, leading to the constitutive activation of BCL3 protein, are rare recurrent chromosomal abnormalities observed in mature B-cell lymphoproliferative disorders, mainly chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).1 BCL3-CLL presents with specific features, such as atypical morphology of lymphocytes, trisomy 12 (+12)
-
Moderate–severe beta-thalassemia intermedia phenotype caused by sextuplicated alpha-globin gene allele in two beta-thalassemia carriers Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-30 Ahlem Achour, Jeroen Knijnenburg, Tamara Koopmann, Amir Raz, Marc Tischkowitz, Thomas D. Coates, F. Baas, C. L. Harteveld
Beta-thalassemia intermedia is caused by homo- or compound heterozygosity for beta-thalassemia variants reducing the beta-globin synthesis and encompasses a wide clinical spectrum ranging from non-transfusion dependent hemolytic anemia to occasional blood transfusion dependency. Carriers of beta-thalassemia are usually clinically asymptomatic. Only rarely beta-thalassemia carriers express symptoms
-
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-28 Tamer Othman, Paul Koller, Ni‐Chun Tsai, Dongyun Yang, Hoda Pourhassan, Vaibhav Agrawal, Dat Ngo, Jason Chen, Leonardo Farol, Ricardo Spielberger, Firoozeh Sahebi, Monzr M. Al Malki, Ji‐Lian Cai, Karamjeet S. Sandhu, Joshua Mansour, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Shukaib Arslan, Guido Marcucci, Stephen J. Forman, Anthony S. Stein, Ryotaro Nakamura, Vinod Pullarkat, Ibrahim Aldoss, Matthew
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post‐HCT, but published clinical experience is primarily with the first‐generation TKI imatinib while
-
SUGP2 p.(Arg639Gln) variant is involved in the pathogenesis of hemochromatosis via the CIRBP/BMPER signaling pathway Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-27 Yanmeng Li, Anjian Xu, Susu Liu, Wei Zhang, Donghu Zhou, Qin OuYang, Huaduan Zi, Bei Zhang, Ning Zhang, Wei Geng, Yiming Zhou, Weijia Duan, Xiaoming Wang, Xinyan Zhao, Xiaojuan Ou, Changfa Fan, Jidong Jia, Jian Huang
-
Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-27 Tamer Othman, Shanpeng Li, Jianying Zhang, Hoda Pourhassan, Vaibhav Agrawal, Dat Ngo, Jason Chen, Leonardo Farol, Firoozeh Sahebi, Karamjeet Sandhu, Ricardo Spielberger, Guido Marcucci, Stephen J. Forman, Anthony S. Stein, Ryotaro Nakamura, Vinod Pullarkat, Matthew Mei, Ibrahim Aldoss, Paul Koller
-
Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-23 Raynier Devillier, Jacques-Emmanuel Galimard, Didier Blaise, Anna Maria Raiola, Stefania Bramanti, Giovanni Grillo, Rocco Pastano, Régis Peffault de Latour, Alessandro Busca, Lucía López-Corral, Arancha Bermúdez Rodríguez, Christoph Schmid, Edouard Forcade, Jan Vydra, Carlos Solano, Gesine Bug, Andreas Neubauer, Amandine Charbonnier, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
In the context of T-cell replete haploidentical stem cell transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy), it is still unknown whether peripheral blood (PB) or bone marrow (BM) is the best graft source. While PB is associated with a higher incidence of graft-versus-host disease (GVHD), it may induce a stronger graft-versus-leukemia effect compared to BM, notably in acute
-
Comparative histological analysis of spleens in pediatric patients with hemolytic anemias: Insights into the pathophysiological mechanisms of spleen destruction in sickle cell anemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-22 Valentine Brousse, Sara El Hoss, Pierre Isnard, Sandrine Laurance, Camille Lambert, Liza Ali, Arnaud Bonnard, Carmen Capito, Sabine Sarnacki, D. Berrebi, Berengère Koehl, Malika Benkerrou, Florence Missud, Laurent Holvoet, Ghislaine Ithier, Mariane de Montalembert, Slimane Allali, Leon Tshilolo, Jacques Diebold, Thierry Jo Molina
-
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-20 Camille Kockerols, Peter J. M. Valk, Stéphanie Dulucq, Franck-Emmanuel Nicolini, François-Xavier Mahon, Ehab Atallah, Michael J. Mauro, Jerald P. Radich, Simona Bernardi, Domenico Russo, Mirko Farina, Silvia Mori, Carlo Gambacorti-Passerini, Ivan Civettini, Liu Lu, David Yeung, Susan Branford, Gioia Colafigli, Massimo Breccia, Pauline Hogenbirk, Joost van Rosmalen, Jan J. Cornelissen, Peter E. Westerweel
Approximately half of chronic phase (CP) CML patients in a stable deep molecular response (DMR; MR4.0; BCR::ABL1<0.01% on the International Scale [IS]) can safely and durably cease their therapy, entering a treatment-free remission (TFR).1-3 The alternative half of patients will show a molecular recurrence (MolR) requiring restarting TKI therapy.3 A longer total TKI treatment duration and DMR duration
-
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-20 Aseel Alsouqi, Gulrayz Ahmed, Juntian Wang, Giulio Cassanello, Aniko Szabo, Alexandra E. Rojek, Peter A. Riedell, Farrukh Awan, Laura Samples, Mazyar Shadman, Marie Hu, Veronika Bachanova, William Wesson, Nausheen Ahmed, Madiha Iqbal, Mohamed A. Kharfan-Dabaja, Michael Scordo, P. Connor Johnson, Yi-Bin Chen, Sawa Ito, Mehdi Hamadani, Matthew Frigault
Secondary central nervous system (CNS) involvement with aggressive B-cell lymphoma (henceforth referred to as SCNSL), either at initial diagnosis, or at the time of disease relapse is associated with poor outcomes. Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of non-Hodgkin lymphomas, however, most pivotal CAR-T trials excluded patients with SCNSL.1 Little is known
-
Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean? Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-20 Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
CONFLICT OF INTEREST STATEMENT None of the authors have any conflict of interest regarding the current manuscript.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-20 Andres Ramirez-Gamero, Humberto Martínez-Cordero, Brady E. Beltrán, Jorge Florindez, Luis Malpica, Jorge J. Castillo
Plasmablastic lymphoma (PBL) is a rare CD20-negative aggressive lymphoma with a poor prognosis under standard treatment options. Though PBL is associated with human immunodeficiency virus infection and other immunosuppressed states, it can also affect immunocompetent individuals.
-
BCR-ABL testing in the evaluation of neutrophilia Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-17 Caleb J. Smith, Gordon J. Ruan, Lindsey Ann Kluck, Mackenzie Maberry, Ronald S. Go
Neutrophilia is a nonspecific peripheral blood abnormality commonly encountered in clinical practice. The differential diagnosis of neutrophilia is broad, including but not limited to reactive states (i.e., infectious or inflammatory conditions), asplenia, tobacco use, iatrogenic from steroid-induced demargination, factitious from laboratory error, and primary clonal disorders.1, 2 The plurality of
-
Paving the path for ongoing clinical research and education in post retirement age Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-17 Tiziano Barbui
-
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-17 Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna Maria Fink, Moritz Fürstenau, Arnon P. Kater, Ellen van der Spek, Carsten Utoft Niemann, Caspar da Cunha-Bang, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Barbara Eichhorst
-
Aspirin use in essential thrombocythemia: Once-daily or twice-daily or not at all? Am. J. Hematol. (IF 10.1) Pub Date : 2024-05-16 Ayalew Tefferi, Tiziano Barbui